Health ProductsDear Healthcare Professional Letter

Archived – Conditional Approval of Viread (Tenofovir Disoproxil Fumarate) – Gilead Sciences, Inc.

· Published by Health Canada · Official notice

Details

Alert type: Dear Healthcare Professional Letter
Category: Drugs
Issue: Important Safety Information
Audience: Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Gilead Sciences, Inc.
Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

[Text of letter begins]

Approval of VIREAD® with conditions

March 8, 2004

Dear Health Professional(s),

Health Canada has issued a conditional marketing authorization under the Notice of Compliance with conditions (NOC/c) policy for Viread® (tenofovir disoproxil fumarate), a new nucleotide reverse transcriptase inhibitor (NtRTI) to reflect the promising nature of the clinical data from studies of Viread and the need for confirmatory studies to verify the clinical benefit seen to date. Gilead Sciences Inc. is pleased to announce that Viread is now available by prescription. Viread is supplied as 300 mg tablets for oral use, packaged in bottles of 30 tablets (DIN 02247128).

Viread is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents in patients 18 years of age and older who have experienced virologic failure on other regimens.

Routine monitoring of renal function is recommended for any patient receiving Viread. Particular caution should be exercised when administering Viread to patients with known risk factors for renal disease or a history of renal dysfunction; however, cases of renal failure have also been reported in patients with no known risk factors. Viread should be avoided with concurrent use of a nephrotoxic agent. Viread should not be administered to patients with renal insufficiency (creatinine clearance < 60 mL/min).

Co-administration of Viread and didanosine should be undertaken with caution. When administered with Viread, the Cmax and AUC of didanosine increased approximately 48 to 64%. Increases in didanosine concentration of this magnitude could potentiate didanosine-associated adverse events, including pancreatitis, lactic acidosis, and neuropathy. Patients receiving combination therapy with Viread and didanosine should be monitored closely and didanosine should be discontinued in patients who develop didanosine-associated adverse events.

Early virologic failure and high rates of resistance mtations have been reported in HIV-infected patients receiving once-daily triple NRTI regimens containing tenofovir disoproxil fumarate (Viread)/lamivudine/didanosine, and tenofovir DF/lamivudine/(investigational as once-daily) abacavir. Tenofovir DF in combination with didanosine and lamivudine or abacavir and lamivudine as a triple antiretroviral therapy is not recommended when considering a new treatment regimen for patients with HIV infection.

Approval of Viread was based on analyses of surrogate endpoints (plasma HIV-1 RNA and CD4 counts) that are predictors of clinical benefit. The clinical studies were conducted in treatment experienced patients, generally with baseline viral loads of less than 10,000 copies per mL. Conditional marketing authorization was based on one Phase III trial and a smaller Phase II trial. Both of these trials were placebo controlled for 24 weeks. There are no study results demonstrating the effect of Viread on the clinical progression of HIV infection. The benefits of Viread in patients with viral loads greater than 10,000 and in antiretroviral naïve patients are unknown; studies are underway to evaluate these patient populations. Patients should be advised about the conditional nature of the marketing authorization for Viread.

Viread is the first nucleotide reverse transcriptase inhibitor (NtRTI) approved for the treatment of HIV infection. In controlled clinical studies, Viread has been shown to reduce the level of HIV in the blood when added to patients' existing antiretroviral regimens (an average reduction of 0.61 log10 copies/mL; n=368).

The most common adverse events in patients receiving Viread in clinical studies were mild to moderate gastrointestinal events, such as nausea, diarrhea, vomiting and flatulence. In general, laboratory abnormalities observed in clinical studies occurred with similar frequency in the Viread and placebo-treated groups.

Adverse events reported with use of Viread during clinical practice include renal insufficiency, kidney failure, Fanconi syndrome, increased creatinine levels, asthenia, pancreatitis, hypophosphatemia, lactic acidosis, dizziness, dyspnea and rash.

Viread is available in 300 mg tablets for oral use, once daily, in combination with other antiretroviral agents for the treatment of HIV infection in patients who have experienced virologic failure on other regimens. Please refer to the product monograph for further details.
For medical inquiries regarding Viread, please contact Gilead Medical Information at 1-800-GILEAD-5.

Sincerely,

Jay Toole, MD, Ph.D.
Senior Vice President
Clinical Research

Any suspected adverse drug reactions (ADR) can be reported to:

Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Health Products Safety Information Division
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
OTTAWA, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
Toll free for consumers and health professionals:
Tel: 866 234-2345, Fax: 866-678-6789
Email: cadrmp@hc-sc.gc.ca

The ADR Reporting Form can be found in The Canadian Compendium of Pharmaceuticals and Specialties, or on the TPD website, along with the ADR Guidelines

[Text of letter ends]
Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime